| Enhancing triage efficiency and accuracy in emergency rooms for patients with metastatic prostate cancer: a retrospective analysis of artificial intelligence-assisted triage … G Gebrael, KK Sahu, B Chigarira, N Tripathi, V Mathew Thomas, ... Cancers 15 (14), 3717, 2023 | 22 | 2023 |
| Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy … G Gebrael, N Sayegh, VM Thomas, B Chigarira, N Tripathi, YJ Jo, H Li, ... Prostate Cancer and Prostatic Diseases, 1-4, 2023 | 3 | 2023 |
| Survival outcomes and characterization of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT … N Sayegh, N Tripathi, B Chigarira, Y Jo, TR McFarland, A Kessel, ... Journal of Clinical Oncology 40 (6_suppl), 123-123, 2022 | 2 | 2022 |
| Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US VM Thomas, Y Jo, N Tripathi, S Roy, B Chigarira, A Narang, G Gebrael, ... JAMA Network Open 7 (5), e249417-e249417, 2024 | 1 | 2024 |
| Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor … G Gebrael, N Sayegh, N Tripathi, D Goel, T McFarland, H Ebrahimi, ... Urology Practice 11 (1), 32-35, 2024 | 1 | 2024 |
| 2380P Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy … N Sayegh, YJ Jo, G Gebrael, N Tripathi, B Chigarira, A Srivastava, ... Annals of Oncology 34, S1212, 2023 | 1 | 2023 |
| Tumor transcriptomic profile in patients (pts) with advanced prostate cancer (PCa) with cribriform and signet ring-like histologies. T Seasor, M Balatico, B Chigarira, KKK Sahu, JT Kim, AP Matynia, ... Journal of Clinical Oncology 41 (6_suppl), 259-259, 2023 | 1 | 2023 |
| Transcriptomic profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (DN-mCSPC) versus those with mCSPC that have relapsed from prior … N Sayegh, B Chigarira, EJ Hernandez, TR McFarland, H Li, KK Sahu, ... Journal of Clinical Oncology 40 (16_suppl), 5080-5080, 2022 | 1 | 2022 |
| Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing … U Swami, B Chigarira, N Sayegh, TR McFarland, N Tripathi, ... Journal of Clinical Oncology 40 (6_suppl), 133-133, 2022 | 1 | 2022 |
| Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy VM Thomas, N Sayegh, B Chigarira, G Gebrael, N Tripathi, ... European Urology Oncology, 2024 | | 2024 |
| Natural course of metastatic castration‐resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone‐sensitive setting G Gebrael, C Hage Chehade, N Sayegh, N Tripathi, B Chigarira, D Goel, ... The Prostate, 2024 | | 2024 |
| Tumor genomic and transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus do not achieve an optimal PSA response … VM Thomas, B Chigarira, G Gebrael, C Chehade, A Narang, N Sayegh, ... Cancer Research 84 (6_Supplement), 1136-1136, 2024 | | 2024 |
| Genomic biomarkers of survival in patients (pts) with metastatic castrate-sensitive prostate cancer (mCSPC) undergoing androgen deprivation therapy (ADT) intensification (ADTi) A Narang, G Gebrael, CH Chehade, N Sayegh, Y Jo, B Chigarira, ... Cancer Research 84 (6_Supplement), 2560-2560, 2024 | | 2024 |
| The utility of ChatGPT in subspecialty consultation for patients (pts) with metastatic genitourinary (GU) cancer. A Srivastava, G Galarza Fortuna, B Chigarira, E Dal, C Hage Chehade, ... Journal of Clinical Oncology 42 (4_suppl), 227-227, 2024 | | 2024 |
| Disease characteristics, survival outcomes, and tumor molecular landscape in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) harboring CDK12 … C Hage Chehade, G Gebrael, A Srivastava, N Tripathi, N Sayegh, ... Journal of Clinical Oncology 42 (4_suppl), 189-189, 2024 | | 2024 |
| Comparative effectiveness of ChatGPT 4.0 and medical oncologists in telemedicine-based management of metastatic prostate carcinoma (mPC). E Dal, A Srivastava, B Chigarira, C Hage Chehade, A Narang, G Gebrael, ... Journal of Clinical Oncology 42 (4_suppl), 226-226, 2024 | | 2024 |
| Treatment (Rx) trends and attrition with lines of therapy in patients (pts) with advanced urothelial carcinoma (aUC). V Mathew Thomas, Y Jo, N Tripathi, S Roy, B Chigarira, E Dal, G Gebrael, ... Journal of Clinical Oncology 42 (4_suppl), 562-562, 2024 | | 2024 |
| Differences in the Tumor Transcriptomic Profile of Patients with Advanced Prostate Cancer with and without Diabetes Mellitus GMG Fortuna, N Tripathi, H Li, B Chigarira, SA Kumar, K JongTaek, ... International Journal of Cancer Care and Delivery 3 (Supplement 2), 2023 | | 2023 |
| Differential Tumor Gene Expression Profiling of Obese and Non-Obese Patients (pts) with Prostatic Adenocarcinoma (PC) VM Thomas, B Chigarira, G Gebrael, N Sayegh, N Tripathi, ... International Journal of Cancer Care and Delivery 3 (Supplement 2), 2023 | | 2023 |
| Correlation of tumor gene expression profile and gleason score (GS) in patients (pts) with metastatic prostate cancer G Gebrael, N Sayegh, N Tripathi, B Chigarira, Y Jo, VM Thomas, ... International Journal of Cancer Care and Delivery 3 (Supplement 2), 2023 | | 2023 |
